Search Results
PARADIGM: Panitumumab plus mFOLFOX6 in RAS wt mCRC
Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
PARADIGM: panitumumab versus bevacizumab in RAS-wt mCRC
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC
How will the PARADIGM trial change the mCRC treatment landscape?
Panitumumab + mFOLOFOX6 as the new standard of care for RAS WT metastatic colorectal cancer
Panitumumab significantly improves OS vs bevacizumab + mFOLFOX6 in patients with RAS WT and left...
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC
mFOLFOXIRI/PAN vs mFOLFOX6/PAN as initial treatment of patients with unresectable RAS & BRAF WT mCRC
ASCO2022 - LBA1: Panitumumab + mFOLFOX6 vs bevacizumab plus mFOLFOX6 1st-line in RAS WT mCRC (P...
Expert Report on panitumumab for first line treatment of RAS wild type mCRC from ASCO 2022
